139 related articles for article (PubMed ID: 33159932)
1. MT
Noseda ACD; Rodrigues LS; Targa ADS; Ilkiw JL; Fagotti J; Dos Santos PD; Cecon E; Markus RP; Solimena M; Jockers R; Lima MMS
Eur J Pharmacol; 2021 Jan; 891():173722. PubMed ID: 33159932
[TBL] [Abstract][Full Text] [Related]
2. Dopaminergic Lesion in the Olfactory Bulb Restores Olfaction and Induces Depressive-Like Behaviors in a 6-OHDA Model of Parkinson's Disease.
Ilkiw JL; Kmita LC; Targa ADS; Noseda ACD; Rodrigues LS; Dorieux FWC; Fagotti J; Dos Santos P; Lima MMS
Mol Neurobiol; 2019 Feb; 56(2):1082-1095. PubMed ID: 29869198
[TBL] [Abstract][Full Text] [Related]
3. Olfactory Bulb D
Alberts T; Antipova V; Holzmann C; Hawlitschka A; Schmitt O; Kurth J; Stenzel J; Lindner T; Krause BJ; Wree A; Witt M
Toxins (Basel); 2022 Jan; 14(2):. PubMed ID: 35202123
[TBL] [Abstract][Full Text] [Related]
4. Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson's disease.
Yang J; Lv DJ; Li LX; Wang YL; Qi D; Chen J; Mao CJ; Wang F; Liu Y; Hu LF; Liu CF
Neurotoxicology; 2019 Jul; 73():175-182. PubMed ID: 30978411
[TBL] [Abstract][Full Text] [Related]
5. The influence od melatonin receptors antagonists, luzindole and 4-phenyl-2-propionamidotetralin (4-P-PDOT), on melatonin-dependent vasopressin and adrenocorticotropic hormone (ACTH) release from the rat hypothalamo-hypophysial system. In vitro and in vivo studies.
Juszczak M; Roszczyk M; Kowalczyk E; Stempniak B
J Physiol Pharmacol; 2014 Dec; 65(6):777-84. PubMed ID: 25554981
[TBL] [Abstract][Full Text] [Related]
6. Melatonin MT
López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
[TBL] [Abstract][Full Text] [Related]
7. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V
Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
[TBL] [Abstract][Full Text] [Related]
8. Partial depletion of dopaminergic neurons in the substantia nigra impairs olfaction and alters neural activity in the olfactory bulb.
Zhang W; Sun C; Shao Y; Zhou Z; Hou Y; Li A
Sci Rep; 2019 Jan; 9(1):254. PubMed ID: 30670747
[TBL] [Abstract][Full Text] [Related]
9. Putative role of monoamines in the antidepressant-like mechanism induced by striatal MT2 blockade.
Noseda AC; Rodrigues LS; Targa AD; Aurich MF; Vital MA; Da Cunha C; Lima MM
Behav Brain Res; 2014 Dec; 275():136-45. PubMed ID: 25218873
[TBL] [Abstract][Full Text] [Related]
10. The nonsteroidal antiinflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model of Parkinson's disease.
Santiago RM; Tonin FS; Barbiero J; Zaminelli T; Boschen SL; Andreatini R; Da Cunha C; Lima MM; Vital MA
Neuroscience; 2015 Aug; 300():246-53. PubMed ID: 25999296
[TBL] [Abstract][Full Text] [Related]
11. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease.
Yildirim FB; Ozsoy O; Tanriover G; Kaya Y; Ogut E; Gemici B; Dilmac S; Ozkan A; Agar A; Aslan M
Neurochem Int; 2014 Dec; 79():1-11. PubMed ID: 25263280
[TBL] [Abstract][Full Text] [Related]
13. A new dopaminergic nigro-olfactory projection.
Höglinger GU; Alvarez-Fischer D; Arias-Carrión O; Djufri M; Windolph A; Keber U; Borta A; Ries V; Schwarting RK; Scheller D; Oertel WH
Acta Neuropathol; 2015 Sep; 130(3):333-48. PubMed ID: 26072303
[TBL] [Abstract][Full Text] [Related]
14. Luzindole but not 4-phenyl-2- propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine Colon 38 cancer growth in vitro.
Winczyk K; Fuss-Chmielewska J; Lawnicka H; Pawlikowski M; Karasek M
Neuro Endocrinol Lett; 2009; 30(5):657-62. PubMed ID: 20035258
[TBL] [Abstract][Full Text] [Related]
15. Melatonin in the mammalian olfactory bulb.
Corthell JT; Olcese J; Trombley PQ
Neuroscience; 2014 Mar; 261():74-84. PubMed ID: 24365461
[TBL] [Abstract][Full Text] [Related]
16. Involvement of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic beta-cells.
Stumpf I; Mühlbauer E; Peschke E
J Pineal Res; 2008 Oct; 45(3):318-27. PubMed ID: 18363673
[TBL] [Abstract][Full Text] [Related]
17. Adaptive down-regulation of the serotonin transporter in the 6-hydroxydopamine-induced rat model of preclinical stages of Parkinson's disease and after chronic pramipexole treatment.
Berghauzen-Maciejewska K; Wardas J; Kosmowska B; Domin H; Śmiałowska M; Głowacka U; Ossowska K
Neuroscience; 2016 Feb; 314():22-34. PubMed ID: 26628402
[TBL] [Abstract][Full Text] [Related]
18. Activation and blockade of serotonin7 receptors in the prelimbic cortex regulate depressive-like behaviors in a 6-hydroxydopamine-induced Parkinson's disease rat model.
Zhang QJ; Du CX; Tan HH; Zhang L; Li LB; Zhang J; Niu XL; Liu J
Neuroscience; 2015 Dec; 311():45-55. PubMed ID: 26470809
[TBL] [Abstract][Full Text] [Related]
19. The role of melatonin membrane receptors in melatonin-dependent oxytocin secretion from the rat hypothalamo-neurohypophysial system - an in vitro and in vivo approach.
Juszczak M; Wolak M; Bojanowska E; Piera L; Roszczyk M
Endokrynol Pol; 2016; 67(5):507-514. PubMed ID: 26884304
[TBL] [Abstract][Full Text] [Related]
20. Short-term effects of melatonin and pinealectomy on serotonergic neuronal activity across the light-dark cycle.
Domínguez-López S; Mahar I; Bambico FR; Labonté B; Ochoa-Sánchez R; Leyton M; Gobbi G
J Psychopharmacol; 2012 Jun; 26(6):830-44. PubMed ID: 21730015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
